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Edith Yuk Ting Tse1 and Yick Pang Ching1,2*Abstract
The p21-activated kinases (PAKs) are downstream effectors of the Rho family small GTPases as well as a wide variety of
mitogenic factors and have been implicated in cancer formation, development and metastasis. PAKs phosphorylate a
wide spectrum of substrates to mediate extracellular signals and regulate cytoskeletal remodeling, cell motility and
survival. In this review, we aim to summarize the findings regarding the oncogenic role and the underlying mechanisms
of PAKs signaling in various cancers, and in particular highlight the prime importance of PAKs in hepatocellular
carcinoma (HCC) progression and metastasis. Recent studies exploring the potential therapeutic application of PAK
inhibitors will also be discussed.
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Liver cancer (hepatocellular carcinoma, HCC) is the fifth
most common cancer in the world and particularly preva-
lent in Eastern Asia including China, Taiwan, Korea and
Japan [1,2]. Hepatocarcinogenesis is a multistep process,
involving the chronic infections of hepatitis B virus (HBV)
and hepatitis c virus (HCV), liver cirrhosis, aflatoxin B1
intake, alcohol abuse and the accumulations of genetic
and epigenetic aberrations, resulting in the dysregulation
of cellular events that perpetuate the hepatocarcinogenesis
process [3]. HCC is often diagnosed at advanced stage
due to the lack of observable symptoms in early stage
HCC. Treatment options of advanced metastasized HCC
are limited as radical surgery, radiotherapy and liver trans-
plantation are effective mainly for localized primary
tumors [4]. As a result, the prognosis is extremely unsatis-
factory with high incidences of postoperative recurrence
and metastasis, leading to poor survival rate of HCC pa-
tients [5]. Molecular targeted therapy is therefore envi-
sioned as potential treatment regimen to improve the
survival benefits of HCC patients. Clarifying the molecular
mechanisms involved in HCC development and metastasis
would definitely warrant the advancement of molecular-
targeted therapies. Recently, PAKs, downstream effectors* Correspondence: ypching@hku.hk
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of mitogenic factors, have been implicated in HCC pro-
gression and metastasis. In this review, we will highlight
the expression and signaling pathways of PAKs in human
cancers, in particular its functional role in hepatocarcino-
genesis, furthermore, the potential therapeutic application
of PAK1 inhibitor will be discussed.Review
PAKs signaling
p21-activated kinases (PAKs) are best characterized as the
downstream effectors of the Rho family small GTPases
Cdc42 and Rac1, which control the formation of filopodia
and lamellipodia respectively [6]. Cdc42 and Rac1 are well
established key regulators of cell migration and invasion
processes involved in cancer metastasis [7], therefore it is
not surprising for PAKs to be implicated in mediating
extracellular signals and regulating cell motility and morph-
ology, cytoskeletal remodeling, cell proliferation and apop-
tosis, thus contributing to cancer formation, development
and metastasis [8].
The PAK family members are categorized into two
groups based on their structural and biochemical discrep-
ancies: PAK1, PAK2 and PAK3 belong to group I, whereas
PAK4, PAK5 and PAK6 belong to group II. The domain
structure of the group I and II PAKs is depicted in Figure 1.
In general, all members of group I PAKs are comprised
of two Src homology 3 (SH-3)-binding motifs and aal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 Domain structure of PAKs. A conserved N-terminal p21/GTPase domain (PBD) and a C-terminal serine/threonine kinase domain are
shared by all family members of PAK. An autoinhibition mechanism is found available in all PAKs. Binding of activated Cdc42 or Rac1 to the PBD
releases group I PAKs from the auto-inhibitory (AID) domain and activates the kinases. AID is also present in PAK5, whereas an autoinhibitory
psuedosubstrate has been indentified in PAK4 and PAK6.
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with an auto-inhibitory domain (AID) at the N-terminal
region and a conserved non-classical SH3-binding site for
the binding of guanine-nucleotide-exchange factor PAK-
interacting exchange factor (PIX) [9], whereas the kinase
domain can be found at the C-terminal. Contrastingly,
only the PBD and kinase domains can be found present in
the group II PAKs, lacking the AID (except PAK5 [10]),
SH3- and PIX-binding domains (Figure 1). Recently, stud-
ies have revealed the presence of an autoinhibitory pseudo-
substrate in PAK4 and PAK6 primary sequences, explaining
the mechanism that underlies the constitutive autoinhibi-
tion of the kinases [11,12]. Both group I and II PAKs have
highly conserved proline-rich domains, the kinase domains
of group I PAKs share a high percentage homology of 92-
95%, while the percentage identity of group II PAKs is
around 80% [13].
Despite the similarity in domain structure and sequence
of PAKs, the two groups actually have a pronounced
difference in terms of regulatory mechanisms, substraterecognitions and cellular functions. For group I PAKs,
binding of GTP-bound active Cdc42 and Rac to the PBD
domain releases the kinase from the inhibition of AID,
as a result, the kinase activity is enhanced [14]. Notably,
binding of adaptor protein Nck and Grb2 to the two SH3-
binding motifs [15,16] suggest the possibility for the
recruitment of group I PAKs to the plasma membrane.
Interestingly, adhesion to extracellular matrix has been
found to be essential for Rac to activate PAK1 [17]. Like-
wise, localization of the PAK1 to the plasma membrane is
indispensible for kinase activation, and the adaptor protein
Nck is believed to mediate the membrane targeting [18]. In
contrast, binding of activated Cdc42 or Rac to group II
PAKs is not necessary for kinase activation, instead such as-
sociation induces the translocation of group II PAKs to
various cellular compartments [19-21]. Binding of activated
Cdc42 to PAK4 targets the kinase to the Golgi apparatus,
leading to actin polymerization [19,22]. Co-expression of
PAK4 and constitutively active Cdc42 dramatically prolongs
filopodia formation; such observation might be ascribed to
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assembly via LIM domain kinase (LIMK) phosphorylation
[23]. For PAK5, association with activated Cdc42 has no ef-
fect on the shuttling of the kinase between mitochondria
and the nucleus, in which PAK5 inhibits apoptosis via
BCL2-associated death promoter (BAD) phosphorylation
[24-26]. Lastly, PAK6 is characterized by its distinctive
FXXMF motif that interacts directly with the androgen re-
ceptor (AR) ligand-binding domain (LBD) [27].
In general, group I PAKs are known to phosphorylate
substrates that play a role in cytoskeleton remodeling
as well as cell survival signaling. PAK1 has been most
extensively characterized among the group I PAKs and
the signaling pathways of PAK1 are shown in Figure 2.
The activity of PAK1 is regulated by a wide spectrum of
upstream signaling molecules, including the small Rho
GTPases Cdc42 and Rac, phosphoinositide-dependent
kinase 1 (PDK1) [28], protein kinase A (PKA) [29],
Phosphoinositide 3-Kinase (PI3K) [30] and AKT via
phosphorylation and protein-protein interaction [31].
Activation of PAK1 by releasing it from the AID and theRTKs/GPCRs
PAK1
Grb2
Nck
Cdc42
Rac1 P
PAK1
Activators
Cell Proliferati
BAD
pS112, pS136
Raf1pS338, pS339
MEK1
pS298
DLC1
pS88
FKHR
pS256
Figure 2 Signaling pathways of PAK1. The well-characterized upstream
Rho GTPases Cdc42 and Rac1, receptor tyrosine kinases mediated growth f
tyrosine kinase adaptor protein 1 (Nck), intergrins, serine/threonine kinases
kinase isozyme 1 (PDK1) and Ras. A wide spectrum of substrates phosphory
light chain 1 (DLC1) and Merlin by PAK1 orchestrate to promote cancer ce
(FKHR), MEK1, MEKK1 and estrogen receptor-α (ER-α) by PAK1 phosphoryla
substrates that regulate cytoskeletal dynamics, including myosin light-chain
cell motility is enhanced as a result.maintenance of kinase activity are resulted from the
phosphorylations of Ser144, Ser199 and Ser204 and
Thr423 [32,33]. Activated PAK1 then acts as an key medi-
ator to control cell proliferation, survival, death and motility
by phosphorylating corresponding downstream substrates
[14]. Some of the important substrates of PAK1 and their
PAK1 phosphorylation sites are depicted in Figure 2. PAK1
has been shown to play a role in cytoskeleton remodeling
to increase cell motility. Activated PAK1 inhibits myosin
light chain (MLC) activity by phosphorylating myosin light
chain kinase (MLCK), resulting in suppression of stress
fiber formation [34]. Alteration of actin dynamics by PAK1
has also been documented. PAK1 phosphorylates and
activates LIMK, which then phosphorylates the actin-
binding protein cofilin, resulting in inhibition of F-
actin-depolymerizing activity [35]. PAK1 stimulates
the actin filament nucleating protein complex Arp2/3
via phosphorylation of its p41-Arc subunit, thereby
inducing cell motility [36]. PAK1 can also interact dir-
ectly with various substrates to promote cell survival.
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activators of PAK1 include the G protein-coupled receptors mediated
actor receptor-bound protein 2 (Grb2) and non-catalytic region of
phosphatidylinositol 3 kinase (PI3K) and pyruvate dehydrogenase
lated directly by PAK1 has been identified. Inhibition of of BAD, dynein
ll survival. Likewise, activation of Raf1, forkhead in rhabdomyosarcoma
tion empower cancer cell to survive. PAK1 also phosphorylates
kinase (MLCK), LIM domain kinase (LIMK), p41-Arc and Merlin,
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shown to directly interact with PAK1. PAK1 phosphory-
lates and induces the transactivation function of ER-α, and
such activation is believed to promote hormone independ-
ence in breast cancer cells [37]. On the other hand, under
the stimulation of estrogen, PAK1 phosphorylates FKHR
and inhibits its nuclear translocation, repressing the ability
of FKHR to activate the Fas ligand promoter that triggers
apoptosis [38]. Likewise, PAK1 phosphorylates the apop-
tosis agonists BAD [39] and dynein light chain 1
(DLC1) [40] to inhibit their inactivating functions on
the pro-survival BCL2 family members. PAK1 can inac-
tivates the tumor suppressor Merlin via phosphoryl-
ation [41], as well as stimulating the mitogen-activated
protein kinase (MAPK) cascades by phosphorylating
Raf-1 [42], MEKK1 [43] as well as MEK1 [44]. The se-
quence of the kinase domain of group I and II PAKs is
rather diverged, sharing around 50% sequence hom-
ology which suggests their difference in substrates rec-
ognitions [45]. Majority of PAK4’s substrates can also be
phosphorylated by PAK1, e.g. LIMK [23], BAD [46], paxil-
lin [47], guanine nucleotide exchange factor-H1 (GEF-H1)
[48] and β-catenin [49]. PAK4 thus plays a role in cyto-
skeletal regulation as well as cell survival pathways.
Dysregulation of PAKs in human cancers
The expression of PAKs in human normal and cancer-
ous tissues is summarized in Table 1. Among the PAKs
family, PAK1 is the most extensively studied member in
group I PAKs; its oncogenic role and the underlying
mechanisms have been investigated in a wide variety of
cancers. PAK1 overexpression has been documented in
various malignancies including breast [50,51], colon [52],
ovarian [53], lung [54], bladder [55] and liver [56] can-
cers. Osada et al. provided the first piece of evidence
that suggested the involvement of PAK1 in cellular
transformation. They found that exogenous introduction
of PBD domain of PAK1 could suppress fibroblast cells
transformation induced by Ras and Rac [57]. It has also
been documented that Ras, Raf-1 and Rac-1 induced NF-
κB activation is PAK1-dependent, and PAK1 could activate
NF-κB as well and stimulated the nuclear translocation ofTable 1 Expression of PAKs in human normal and cancerous
Normal tissue
Group I PAK 1 Brain, muscle, spleen [6]
PAK 2 Ubiquitously expressed in most tissue
PAK 3 Brain [87]
Group II PAK 4 Ubiquitously expressed in most tissue
predominantly in prostate, testis and
PAK 5 Brain [20]
PAK 6 Brain, testis, prostate, kidney [21,45]NF-κB p65 subunit [58]. In contrast, kinase dead mutant of
PAK1 abolished the Ras-induced transformation in fibro-
blasts, demonstrating the critical role of PAK1 kinase activ-
ity in cellular transformation as well as Ras signaling [59].
Similarly, PAK1 overexpression induced lamellipodia and
filopodia formations in quiescent Swiss 3T3 cells, increased
cell motility via destabilization of actin stress fibres and the
increase of focal adhesions turnover, suggesting its role in
cancer metastasis [60,61].
In breast cancer, the activity of PAK1 is upregulated by
various mechanisms. PAK1 overexpression was frequently
observed and associated with breast cancer invasiveness. It
was shown that PAK1 could upregulate cyclin D1 tran-
scription in breast cancer cells thus fueling the cells with
proliferative advantage [50]. Introduction of kinase-active
PAK1 encouraged anchorage-independent growth and
dysregulate mitotic spindles formation; the MAPK and c-
Jun NH2-terminal kinase (JNK) activities were upregulated
as well [62]. Conversely, ectopic expression of kinase dead
K299R PAK1 suppressed JNK activity as well as the AP-1
promoter transcription activity, which is known to tran-
scribe genes that involved in breast cancer invasiveness.
Moreover, the phenotypic and morphogenic alterations re-
sulted from K299R PAK1 expression included stabilization
of focal adhesions and stress fibers as well as extensive cell
spreading, thus reducing the motility and invasiveness of
breast cancer cells [63]. Notably, PAK1 overexpression
and nuclear localization were associated with Tamoxifen
resistance [51], which might be explained by the ability of
PAK1 to directly phosphorylate and transactivate the es-
trogen receptor-α (ER-α) [37]. The involvement of PAK1
in angiogenesis was revealed by the induction of vascular
endothelial growth factor (VEGF) by dominant-active mu-
tant of PAK1 in breast cancer cell [64]. Other than upreg-
ulating PAK1, hyperactivity of small GTPases Rac3 was
found to augment the kinase activity of PAK1 in breast
cancer [65]. Taken together, these findings provided com-
pelling evidences that PAK1 is critical in breast cancer
progression and metastasis.
The oncogenic role of PAK1 has also been studied in
other cancers. In ovarian cancer, expression levels of PAK1,
PAK2 and their phosphorylated forms were upregulated intissues
Overexpression in cancer
Bladder [55], breast [50,51], colon [52], liver [56],
lung [54], kidney [85]; ovarian [53,86]
s Liver [74], ovarian [86]
s,
colon [19,22]
Colon [22], liver [76], pancreas [88]
Colon [89], liver [77]
Prostate [90], liver [78]
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and nuclear phospho-PAK1 were associated with ad-
vanced tumor grade and poor survival rate. In search of
the functional effect of PAK1 in ovarian cancer, knock-
down of PAK1 markedly inhibited cell motility and inva-
siveness, accompanied by suppressed p38 activity and
VEGF expression. Increased PAK1 expression was also
found in colorectal cancer progression and significantly
associated with lymph node metastases [52]. In 25% of
squamous NSCLC tumors, PAK1 was found to localize in
nucleus and its expression was associated with the accu-
mulation of myeloid cell leukemia-1 (Mcl-1), which is an
anti-apoptotic BCL2 family member protein. Knockdown
of PAK1 could significantly suppress in vitro and in vivo
tumor cell growth [54]. The anti-apoptotic effect of PAK1
is ascribed to its ability to phosphorylate BAD, a pro-
apoptotic protein that regulates the intrinsic cell death
machinery, causing BAD to dissociate from BCL2 and
associate with 14-3-3tau, cell survival is promoted as a
result, thus empowering tumor cells the advantage to
proliferate [39].
PAK4 from group II PAKs is also implicated in onco-
genic transformation. PAK4 is overexpressed in various
cancer cell lines and Ras related tumors [22,66,67]. PAK4
activity is essential to support the anchorage-independent
growth of cancer cells induced by Ras. Constitutively
active PAK4 mutant S474E was found to transform
NIH3T3 cells. Conversely, kinase-inactive PAK4 K350A
and K351A abrogated the Ras-driven oncogenic trans-
formation and suppressed the anchorage-independent
growth of colon cancer cells [22]. Mechanistically,
PAK4 was shown to exhibit anti-apopototic function by
inhibiting the pro-apoptotic protein BAD as well as the
caspases activity [46].
The oncogenic functions of PAKs in HCC
The oncogenic role of PAKs has been shown in HCC,
particularly in enhancing HCC progression and metasta-
sis by promoting the motility and invasiveness of HCC
cell. PAK1 overexpression was frequently observed in
HCC and significantly associated with more aggressive
and metastatic tumor phenotypes as well as advanced
tumor stage. Overexpression of PAK1 mRNA was found
in 75% of tumorous tissues and associated significantly
with the presence of venous invasion, poor cellular differ-
entiation, advanced tumor stages as well as shorter
disease-free survival. Interestingly, PAK1 protein was
expressed at the membrane of non-tumorous hepatocytes,
while it was detected in both the membrane and cyto-
plasm of HCC cells. Ectopic expression of PAK1 enhanced
HCC cell motility by suppressing stress fiber and focal
adhesion complex formation, suggesting the role of PAK1
in HCC metastasis. Mechanistically, PAK1 was found to
activate JNK and subsequently phosphorylate paxillin atSer178 [56]. Notably, in a diethylnitrosamine (DEN)-
induced liver carcinogenesis animal model, PAK1 overex-
pression was observed along HCC progression, together
with the upregulation of cyclin D1 and activation of
ERK1/2, p38 as well as JNK1/2 kinases [68], strongly sug-
gesting its contribution in HCC development and progres-
sion. In agreement with the oncogenic effect of PAK1 in
HCC, treatment of IPA-3 (2,2-dihydroxy-1,1-dinaphthyla-
disuifide), a highly selective non-ATP-competitive allo-
steric PAK1 inhibitor, could markedly suppress the in vitro
and in vivo growth of HCC via induction of apoptosis and
inhibition of NF-κB activation [69]. PAK1 activation has
consistently been shown to promote anoikis resistance
in hepatoma cells. Activation of VEGFR2/PAK1 and
EGFR/PAK1 signaling, by the expression of Klotho and
N-acetylglucosaminyltransferase V respectively, inhib-
ited anoikis and such effect could be reversed by treat-
ment of PAK1 inhibitor IPA-3 [70,71]. HBV infection is
a well-established risk factor for HCC development; in
fact, chronic HBV infection is associated with majority
of HCC cases. Xu et al. has shown that PAK1 expres-
sion could be induced by the introduction of hepatitis B
virus X protein (HBx) to hepatoma cells. Expression of
HBx favored anchorage-independent growth as well as
anoikis resistance via the upregulation of mitochondrial
BCL2 and PAK1 levels. Knockdown of PAK1 suppressed
in vivo tumor growth of HBx expressing cells as well as
their resistance to anoikis. Indeed, clincopathological
analyses revealed a significant correlation of PAK1 with
HBV infection, poor prognosis and portal vein tumor
thrombosis [72]. Interestingly, PAK1 activation by the
mammalian target of rapamycin (mTOR)/p70 S6 kinase
rather resulted in the suppression of HCV replication
[73]. Sato et al. demonstrated the central role of PAK2
in mediating transforming growth factor-beta (TGF-β)
signaling. TGF-β treatment induced hepatoma cell mi-
gration via phosphorylation of AKT and PAK2, while
treatment of AKT inhibitor inhibited PAK2 phosphoryl-
ation, indicating PAK2 as a downstream mediator of
TGF-β and AKT signaling. Inversely, downregulation of
PAK2 expression impeded cell motility induced by
TGF-β treatment by increasing focal adhesions forma-
tion. Clinically, the expression of phosphorylated PAK2
was significantly correlated with HCC progression and
metastasis [74].
Similar to group I PAKs, group II PAKs play a definitive
role in HCC growth and metastasis as well. A study of
miRNomes in HCC identified a suppression of miR-199a/
b-3p in HCC as compared to normal liver, and such dim-
inution was significantly correlated to poor survival rate.
Interestingly, miR-199a/b-3p actually targeted PAK4 and
subsequently inhibited the PAK4/Raf/MEK/ERK signaling
pathway, leading to HCC growth suppression [75]. Mak
et al. identified CDK5RAP3 as a novel binding partner of
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pressed in HCC with a significant correlation with PAK4
expression. Mechanistically, binding of CDK5RAP3 to
PAK4 activated the kinase and subsequently enhanced the
invasiveness of HCC cells [76]. Overexpression of PAK5
mRNA was also noted in 83% (25/30) of HCC samples
and numerous HCC cell lines, in vitro studies showed that
knockdown of PAK5 markedly inhibited cell proliferation
and induced G1 cell cycle arrest. Downregulation of PAK5
could also suppress the in vivo tumor formation, accom-
panied by diminution of cyclin D1 and β-catenin [77].
Overexpression of PAK6 protein was found in 50% (60/
121) HCC samples whereas the non-tumorous tissues
showed no or low PAK6 expression. PAK6 expression was
significantly correlated with high-grade tumors as well as
the formation of multiple tumor nodules and notably with
poor overall survival, serving as an independent prognos-
tic marker for HCC [78]. Taken together, these studies
underscore the prime importance of PAKs in HCC pro-
gression and metastasis, intervening PAKs signaling thus
holds the promise of more effective therapeutic approach
for HCC.
Potential therapeutic application of PAK inhibitors
Hyperactivation of PAK1 has been reported in numerous
cancers, thus making PAK1 appealing as pharmaco-
logical target for gene therapy. Several small chemical
molecules like FRAX-597 and FL172 have been reported
to inhibit PAK1 activity by targeting the ATP-binding or
kinase catalytic site, yet their specificity towards PAK1 is
unsatisfactory [79,80]. Peptides derived from the auto-
inhibitory domain of PAK1 have been used to block the
kinase activity, however the efficacy of such alternative
approach remains to be evaluated [81]. Recently, Deacon
et al. has reported the identification of a specific allo-
steric inhibitor of PAK1, called IPA-3 [82], which was
suggested to bind and stabilize the auto-inhibitory do-
main of PAK1, resulting in inhibition of PAK1 activation.
However, such suggestion needs to be proved by further
study of the structures of IPA-3 and PAK1 complex,
moreover, the fact that IPA-3 inhibits PAK1 activity at
micro-molar level greatly impedes its application as a
therapeutic drug. Our recent study has shown that IPA-
3 suppressed the growth of HCC tumor in nude mouse,
blocked the activation of NF-κB via PAK1 inhibition and
attenuated the survival signal of HCC cells [69]. Overex-
pression of PAK1 is frequently observed in metastatic
HCC, thus making IPA-3 an attractive therapeutic agent
in treating advanced liver cancer.
As for group II PAK inhibitors, LCH-7749944 and PF-
3758309, which are small-molecule inhibitors of PAK4,
have been examined in recent years [83,84]. LCH-7749944
was found to suppress gastric cancer cell proliferation and
invasion via inhibition of the PAK4/c-Src/EGFR/cyclin D1,PAK4/LIMK1/cofilin and PAK4/MEK-1/ERK1/2/MMP2
pathways [84]. The pyrrolopyrazole inhibitor PF-3758309,
which was isolated from a high-throughput screening of
molecules that inhibit both Group I and II PAKs activity,
has been shown to suppress in vivo cancer cell growth
[83]. However, due to its ATP-competitive nature, it is
likely for PF-3758309 to exhibit strong toxicity on non-
tumorous cells. To conclude, despite the effectiveness of
PAKs inhibitors to suppress cancer cell growth and inva-
sion, further investigations and modifications have to be
done before applying the inhibitors clinically.
Concluding remarks
Dysregulation of PAKs signaling plays an unequivocal
role in the development of numerous cancers; its role in
HCC metastasis has been clearly shown and supported
by evidences from various lines of studies. As a medi-
ator, PAKs converge the extracellular signals, interact
and phosphorylate pools of intracellular substrates,
resulting in the promotion of cancer cell survival and
invasiveness. It is enormously important to target PAKs
due to the central role these kinases play in cancer pro-
gression. Despite the fact that PAK1 and PAK4 inhibi-
tors hold promise for anticancer therapy, achieving this
clinically remains a continuous challenge to researcher.
Abbreviations
HCC: Hepatocellular carcinoma; HBV: Hepatitus B virus; HCV: Hepatitus C
virus; PAKs: p21-activated kinases; SH3: Src homology 3; PBD: p21-binding
domain; AID: Auto-inhibitory domain; PIX: Pak-interacting exchange factor;
LIMK: LIM domain kinase; BAD: BCL2-associated death promoter;
AR: Androgen receptor; LBD: Ligand-binding domain;
PDK1: Phosphoinositide-dependent kinase 1; PKA: Protein kinase A;
PI3K: Phosphoinositide 3-kinase; MLC: Myosin light chain; MLCK: Myosin light
chain kinase; FKHR: Forkhead in rhabdomyosarcoma; DLC1: Dynein light chain
1; MAPK: Mitogen-activated protein kinase; GEF-H1: Guanine nucleotide
exchange factor-H1; JNK: c-Jun NH2-terminal kinase; ER-α: Estrogen receptor-α;
VEGF: Vascular endothelial growth factor; Mcl-1: Myeloid cell leukemia-1;
DEN: Diethylnitrosamine; HBx: Hepatitis B virus X protein; mTOR: Mammalian
target of rapamycin; TGF-β: Transforming growth factor-beta.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Both authors reviewed the literature in this review, drafted, prepared
approved the manuscript.
Acknowledgements
This work is financially supported by Research Fund for the Control of
Infectious Diseases, Hong Kong Government (No. 09080782).
Received: 2 May 2014 Accepted: 18 July 2014
Published: 1 August 2014
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002.
CA Cancer J Clin 2005, 55(2):74–108.
2. El-Serag HB, Rudolph KL: Hepatocellular carcinoma: epidemiology and
molecular carcinogenesis. Gastroenterology 2007, 132(7):2557–2576.
3. Yam JW, Wong CM, Ng IO: Molecular and functional genetics of
hepatocellular carcinoma. Front Biosci (Schol Ed) 2010, 2:117–134.
Tse and Ching Journal of Molecular Signaling 2014, 9:7 Page 7 of 9
http://www.jmolecularsignaling.com/content/9/1/74. Bruix J, Sherman M: Management of hepatocellular carcinoma.
Hepatology 2005, 42(5):1208–1236.
5. Tang ZY: Hepatocellular carcinoma–cause, treatment and metastasis.
World J Gastroenterol 2001, 7(4):445–454.
6. Manser E, Leung T, Salihuddin H, Zhao ZS, Lim L: A brain serine/
threonine protein kinase activated by Cdc42 and Rac1. Nature 1994,
367(6458):40–46.
7. Vega FM, Ridley AJ: Rho GTPases in cancer cell biology. FEBS Lett 2008,
582(14):2093–2101.
8. Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R: PAK signaling in
oncogenesis. Oncogene 2009, 28(28):2545–2555.
9. Manser E, Loo TH, Koh CG, Zhao ZS, Chen XQ, Tan L, Tan I, Leung T, Lim L:
PAK kinases are directly coupled to the PIX family of nucleotide
exchange factors. Mol Cell 1998, 1(2):183–192.
10. Ching YP, Leong VY, Wong CM, Kung HF: Identification of an
autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem
2003, 278(36):33621–33624.
11. Ha BH, Davis MJ, Chen C, Lou HJ, Gao J, Zhang R, Krauthammer M, Halaban R,
Schlessinger J, Turk BE, Boggon TJ: Type II p21-activated kinases (PAKs) are
regulated by an autoinhibitory pseudosubstrate. Proc Natl Acad Sci U S A
2012, 109(40):16107–16112.
12. Wang W, Lim L, Baskaran Y, Manser E, Song J: NMR binding and crystal
structure reveal that intrinsically-unstructured regulatory domain
auto-inhibits PAK4 by a mechanism different from that of PAK1.
Biochem Biophys Res Commun 2013, 438(1):169–174.
13. Whale A, Hashim FN, Fram S, Jones GE, Wells CM: Signalling to cancer
cell invasion through PAK family kinases. Front Biosci (Landmark Ed)
2011, 16:849–864.
14. Bokoch GM: Biology of the p21-activated kinases. Annu Rev Biochem 2003,
72:743–781.
15. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG: Interaction
of the Nck adapter protein with p21-activated kinase (PAK1). J Biol Chem
1996, 271(42):25746–25749.
16. Puto LA, Pestonjamasp K, King CC, Bokoch GM: p21-activated kinase 1
(PAK1) interacts with the Grb2 adapter protein to couple to growth
factor signaling. J Biol Chem 2003, 278(11):9388–9393.
17. del Pozo MA, Price LS, Alderson NB, Ren XD, Schwartz MA: Adhesion to the
extracellular matrix regulates the coupling of the small GTPase Rac to its
effector PAK. Embo J 2000, 19(9):2008–2014.
18. Lu W, Katz S, Gupta R, Mayer BJ: Activation of Pak by membrane
localization mediated by an SH3 domain from the adaptor protein Nck.
Curr Biol 1997, 7(2):85–94.
19. Abo A, Qu J, Cammarano MS, Dan C, Fritsch A, Baud V, Belisle B, Minden A:
PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization
of the actin cytoskeleton and in the formation of filopodia. Embo J
1998, 17(22):6527–6540.
20. Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E,
Khosravi-Far R, Blagoev B, Mann M: Cloning and characterization of PAK5,
a novel member of mammalian p21-activated kinase-II subfamily that is
predominantly expressed in brain. Oncogene 2002, 21(24):3939–3948.
21. Yang F, Li X, Sharma M, Zarnegar M, Lim B, Sun Z: Androgen receptor
specifically interacts with a novel p21-activated kinase, PAK6. J Biol Chem
2001, 276(18):15345–15353.
22. Callow MG, Clairvoyant F, Zhu S, Schryver B, Whyte DB, Bischoff JR, Jallal B,
Smeal T: Requirement for PAK4 in the anchorage-independent growth of
human cancer cell lines. J Biol Chem 2002, 277(1):550–558.
23. Dan C, Kelly A, Bernard O, Minden A: Cytoskeletal changes regulated by
the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and
cofilin. J Biol Chem 2001, 276(34):32115–32121.
24. Cotteret S, Jaffer ZM, Beeser A, Chernoff J: p21-Activated kinase 5 (Pak5)
localizes to mitochondria and inhibits apoptosis by phosphorylating
BAD. Mol Cell Biol 2003, 23(16):5526–5539.
25. Cotteret S, Chernoff J: Nucleocytoplasmic shuttling of Pak5 regulates its
antiapoptotic properties. Mol Cell Biol 2006, 26(8):3215–3230.
26. Wu X, Frost JA: Multiple Rho proteins regulate the subcellular targeting
of PAK5. Biochem Biophys Res Commun 2006, 351(2):328–335.
27. van de Wijngaart DJ, van Royen ME, Hersmus R, Pike AC, Houtsmuller AB,
Jenster G, Trapman J, Dubbink HJ: Novel FXXFF and FXXMF motifs in
androgen receptor cofactors mediate high affinity and specific
interactions with the ligand-binding domain. J Biol Chem 2006,
281(28):19407–19416.28. King CC, Gardiner EM, Zenke FT, Bohl BP, Newton AC, Hemmings BA,
Bokoch GM: p21-activated kinase (PAK1) is phosphorylated and activated
by 3-phosphoinositide-dependent kinase-1 (PDK1). J Biol Chem 2000,
275(52):41201–41209.
29. Howe AK, Juliano RL: Regulation of anchorage-dependent signal
transduction by protein kinase A and p21-activated kinase. Nat Cell Biol
2000, 2(9):593–600.
30. Tsakiridis T, Taha C, Grinstein S, Klip A: Insulin activates a p21-activated
kinase in muscle cells via phosphatidylinositol 3-kinase. J Biol Chem 1996,
271(33):19664–19667.
31. Tang Y, Zhou H, Chen A, Pittman RN, Field J: The Akt proto-oncogene links
Ras to Pak and cell survival signals. J Biol Chem 2000, 275(13):9106–9109.
32. Chong C, Tan L, Lim L, Manser E: The mechanism of PAK activation.
Autophosphorylation events in both regulatory and kinase domains
control activity. J Biol Chem 2001, 276(20):17347–17353.
33. Gatti A, Huang Z, Tuazon PT, Traugh JA: Multisite autophosphorylation of
p21-activated protein kinase gamma-PAK as a function of activation.
J Biol Chem 1999, 274(12):8022–8028.
34. Chew TL, Masaracchia RA, Goeckeler ZM, Wysolmerski RB: Phosphorylation
of non-muscle myosin II regulatory light chain by p21-activated kinase
(gamma-PAK). J Muscle Res Cell Motil 1998, 19(8):839–854.
35. Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by
Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal
dynamics. Nat Cell Biol 1999, 1(5):253–259.
36. Vadlamudi RK, Li F, Barnes CJ, Bagheri-Yarmand R, Kumar R: p41-Arc subunit
of human Arp2/3 complex is a p21-activated kinase-1-interacting
substrate. EMBO Rep 2004, 5(2):154–160.
37. Rayala SK, Talukder AH, Balasenthil S, Tharakan R, Barnes CJ, Wang RA,
Aldaz CM, Khan S, Kumar R: P21-activated kinase 1 regulation of
estrogen receptor-alpha activation involves serine 305 activation
linked with serine 118 phosphorylation. Cancer Res 2006,
66(3):1694–1701.
38. Mazumdar A, Kumar R: Estrogen regulation of Pak1 and FKHR pathways
in breast cancer cells. FEBS Lett 2003, 535(1–3):6–10.
39. Schurmann A, Mooney AF, Sanders LC, Sells MA, Wang HG, Reed JC,
Bokoch GM: p21-activated kinase 1 phosphorylates the death agonist
bad and protects cells from apoptosis. Mol Cell Biol 2000, 20(2):453–461.
40. Vadlamudi RK, Bagheri-Yarmand R, Yang Z, Balasenthil S, Nguyen D, Sahin AA,
den Hollander P, Kumar R: Dynein light chain 1, a p21-activated kinase
1-interacting substrate, promotes cancerous phenotypes. Cancer Cell 2004,
5(6):575–585.
41. Xiao GH, Beeser A, Chernoff J, Testa JR: p21-activated kinase links Rac/
Cdc42 signaling to merlin. J Biol Chem 2002, 277(2):883–886.
42. Chaudhary A, King WG, Mattaliano MD, Frost JA, Diaz B, Morrison DK,
Cobb MH, Marshall MS, Brugge JS: Phosphatidylinositol 3-kinase
regulates Raf1 through Pak phosphorylation of serine 338. Curr Biol
2000, 10(9):551–554.
43. Gallagher ED, Xu S, Moomaw C, Slaughter CA, Cobb MH: Binding of JNK/
SAPK to MEKK1 is regulated by phosphorylation. J Biol Chem 2002,
277(48):45785–45792.
44. Frost JA, Steen H, Shapiro P, Lewis T, Ahn N, Shaw PE, Cobb MH:
Cross-cascade activation of ERKs and ternary complex factors by Rho
family proteins. Embo J 1997, 16(21):6426–6438.
45. Jaffer ZM, Chernoff J: p21-activated kinases: three more join the Pak. Int J
Biochem Cell Biol 2002, 34(7):713–717.
46. Gnesutta N, Qu J, Minden A: The serine/threonine kinase PAK4 prevents
caspase activation and protects cells from apoptosis. J Biol Chem 2001,
276(17):14414–14419.
47. Wells CM, Whale AD, Parsons M, Masters JR, Jones GE: PAK4: a pluripotent
kinase that regulates prostate cancer cell adhesion. J Cell Sci 2010,
123(Pt 10):1663–1673.
48. Callow MG, Zozulya S, Gishizky ML, Jallal B, Smeal T: PAK4 mediates
morphological changes through the regulation of GEF-H1. J Cell Sci 2005,
118(Pt 9):1861–1872.
49. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Gu H, Li F: Nucleo-cytoplasmic
shuttling of PAK4 modulates beta-catenin intracellular translocation and
signaling. Biochim Biophys Acta 2012, 1823(2):465–475.
50. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK,
Kumar R: p21-activated kinase-1 signaling mediates cyclin D1
expression in mammary epithelial and cancer cells. J Biol Chem 2004,
279(2):1422–1428.
Tse and Ching Journal of Molecular Signaling 2014, 9:7 Page 8 of 9
http://www.jmolecularsignaling.com/content/9/1/751. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G: Association
between Pak1 expression and subcellular localization and tamoxifen
resistance in breast cancer patients. J Natl Cancer Inst 2006,
98(10):671–680.
52. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO,
Konicek S, Hom J, Marshall M, Graff JR: Pak-1 expression increases with
progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004,
10(10):3448–3456.
53. Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, Ruffalo T,
King W, Wilber K, Mihatsch MJ, Moch H: Combined array comparative
genomic hybridization and tissue microarray analysis suggest PAK1 at
11q13.5-q14 as a critical oncogene target in ovarian carcinoma. Am J
Pathol 2003, 163(3):985–992.
54. Ong CC, Jubb AM, Haverty PM, Zhou W, Tran V, Truong T, Turley H, O'Brien T,
Vucic D, Harris AL, Belvin M, Friedman LS, Blackwood EM, Koeppen H, Hoeflich
KP: Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor
cells. Proc Natl Acad Sci U S A 2011, 108(17):7177–7182.
55. Ito M, Nishiyama H, Kawanishi H, Matsui S, Guilford P, Reeve A, Ogawa O:
P21-activated kinase 1: a new molecular marker for intravesical
recurrence after transurethral resection of bladder cancer. J Urol 2007,
178(3 Pt 1):1073–1079.
56. Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO: P21-activated protein
kinase is overexpressed in hepatocellular carcinoma and enhances
cancer metastasis involving c-Jun NH2-terminal kinase activation and
paxillin phosphorylation. Cancer Res 2007, 67(8):3601–3608.
57. Osada S, Izawa M, Koyama T, Hirai S, Ohno S: A domain containing the
Cdc42/Rac interactive binding (CRIB) region of p65PAK inhibits
transcriptional activation and cell transformation mediated by the
Ras-Rac pathway. FEBS Lett 1997, 404(2–3):227–233.
58. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH: Stimulation of
NFkappa B activity by multiple signaling pathways requires PAK1. J Biol
Chem 2000, 275(26):19693–19699.
59. Tang Y, Chen Z, Ambrose D, Liu J, Gibbs JB, Chernoff J, Field J: Kinase-
deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts.
Mol Cell Biol 1997, 17(8):4454–4464.
60. Sells MA, Knaus UG, Bagrodia S, Ambrose DM, Bokoch GM, Chernoff J:
Human p21-activated kinase (Pak1) regulates actin organization in
mammalian cells. Curr Biol 1997, 7(3):202–210.
61. Manser E, Huang HY, Loo TH, Chen XQ, Dong JM, Leung T, Lim L:
Expression of constitutively active alpha-PAK reveals effects of the kinase
on actin and focal complexes. Mol Cell Biol 1997, 17(3):1129–1143.
62. Vadlamudi RK, Adam L, Wang RA, Mandal M, Nguyen D, Sahin A, Chernoff J,
Hung MC, Kumar R: Regulatable expression of p21-activated kinase-1
promotes anchorage-independent growth and abnormal organization of
mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000,
275(46):36238–36244.
63. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R: Regulation of
microfilament reorganization and invasiveness of breast cancer cells by
kinase dead p21-activated kinase-1. J Biol Chem 2000, 275(16):12041–12050.
64. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R:
Vascular endothelial growth factor up-regulation via p21-activated
kinase-1 signaling regulates heregulin-beta1-mediated angiogenesis.
J Biol Chem 2000, 275(50):39451–39457.
65. Mira JP, Benard V, Groffen J, Sanders LC, Knaus UG: Endogenous,
hyperactive Rac3 controls proliferation of breast cancer cells by a
p21-activated kinase-dependent pathway. Proc Natl Acad Sci U S A 2000,
97(1):185–189.
66. Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L,
Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B,
Lengauer C, Velculescu VE: Colorectal cancer: mutations in a signalling
pathway. Nature 2005, 436(7052):792.
67. Chen S, Auletta T, Dovirak O, Hutter C, Kuntz K, El-ftesi S, Kendall J, Han H,
von Hoff DD, Ashfaq R, Maitra A, Iacobuzio-Donahue CA, Hruban RH, Lucito
R: Copy number alterations in pancreatic cancer identify recurrent PAK4
amplification. Cancer Biol Ther 2008, 7(11):1793–1802.
68. Parekh P, Rao KV: Overexpression of cyclin D1 is associated with elevated
levels of MAP kinases, Akt and Pak1 during diethylnitrosamine-induced
progressive liver carcinogenesis. Cell Biol Int 2007, 31(1):35–43.
69. Wong LL, Lam IP, Wong TY, Lai WL, Liu HF, Yeung LL, Ching YP: IPA-3
inhibits the growth of liver cancer cells by suppressing PAK1 and
NF-kappaB activation. PLoS One 2013, 8(7):e68843.70. Chen L, Liu H, Liu J, Zhu Y, Xu L, He H, Zhang H, Wang S, Wu Q, Liu W, Liu Y,
Pan D, Ren S, Xu J, Gu J: Klotho endows hepatoma cells with resistance to
anoikis via VEGFR2/PAK1 activation in hepatocellular carcinoma. PLoS One
2013, 8(3):e58413.
71. Liu J, Liu H, Zhang W, Wu Q, Liu W, Liu Y, Pan D, Xu J, Gu J:
N-acetylglucosaminyltransferase V confers hepatoma cells with
resistance to anoikis through EGFR/PAK1 activation. Glycobiology
2013, 23(9):1097–1109.
72. Xu J, Liu H, Chen L, Wang S, Zhou L, Yun X, Sun L, Wen Y, Gu J: Hepatitis B
virus X protein confers resistance of hepatoma cells to anoikis by
up-regulating and activating p21-activated kinase 1. Gastroenterology
2012, 143(1):199–212. e194.
73. Ishida H, Li K, Yi M, Lemon SM: p21-activated kinase 1 is activated
through the mammalian target of rapamycin/p70 S6 kinase pathway
and regulates the replication of hepatitis C virus in human hepatoma
cells. J Biol Chem 2007, 282(16):11836–11848.
74. Sato M, Matsuda Y, Wakai T, Kubota M, Osawa M, Fujimaki S, Sanpei A,
Takamura M, Yamagiwa S, Aoyagi Y: P21-activated kinase-2 is a critical
mediator of transforming growth factor-beta-induced hepatoma cell
migration. J Gastroenterol Hepatol 2013, 28(6):1047–1055.
75. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y,
Tian W, Zhang Q, Wang C, Zhuang SM, Zheng L, Liang A, Tao W, Cao X:
Identification of miRNomes in human liver and hepatocellular carcinoma
reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma.
Cancer Cell 2011, 19(2):232–243.
76. Mak GW, Chan MM, Leong VY, Lee JM, Yau TO, Ng IO, Ching YP:
Overexpression of a novel activator of PAK4, the CDK5 kinase-associated
protein CDK5RAP3, promotes hepatocellular carcinoma metastasis.
Cancer Res 2011, 71(8):2949–2958.
77. Fang ZP, Jiang BG, Gu XF, Zhao B, Ge RL, Zhang FB: P21-activated
kinase 5 plays essential roles in the proliferation and tumorigenicity
of human hepatocellular carcinoma. Acta Pharmacol Sin 2014,
35(1):82–88.
78. Chen H, Miao J, Li H, Wang C, Li J, Zhu Y, Wang J, Wu X, Qiao H: Expression
and prognostic significance of p21-activated kinase 6 in hepatocellular
carcinoma. J Surg Res 2014, 189(1):81–88.
79. Licciulli S, Maksimoska J, Zhou C, Troutman S, Kota S, Liu Q, Duron S,
Campbell D, Chernoff J, Field J, Marmorstein R, Kissil JL: FRAX597, a small
molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of
neurofibromatosis type 2 (NF2)-associated Schwannomas. J Biol Chem
2013, 288(40):29105–29114.
80. Maksimoska J, Feng L, Harms K, Yi C, Kissil J, Marmorstein R, Meggers E:
Targeting large kinase active site with rigid, bulky octahedral ruthenium
complexes. J Am Chem Soc 2008, 130(47):15764–15765.
81. Kumar R, Gururaj AE, Barnes CJ: p21-activated kinases in cancer. Nat Rev
Cancer 2006, 6(6):459–471.
82. Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J,
Peterson JR: An isoform-selective, small-molecule inhibitor targets the
autoregulatory mechanism of p21-activated kinase. Chem Biol 2008,
15(4):322–331.
83. Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J,
Dagostino E, Knighton D, Loi CM, Zager M, Kraynov E, Popoff I,
Christensen JG, Martinez R, Kephart SE, Marakovits J, Karlicek S, Bergqvist
S, Smeal T: Small-molecule p21-activated kinase inhibitor PF-3758309
is a potent inhibitor of oncogenic signaling and tumor growth.
Proc Natl Acad Sci U S A 2010, 107(20):9446–9451.
84. Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, Cheng M, Zhao D, Li F:
LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor,
suppresses proliferation and invasion in human gastric cancer cells.
Cancer Lett 2012, 317(1):24–32.
85. O'Sullivan GC, Tangney M, Casey G, Ambrose M, Houston A, Barry OP:
Modulation of p21-activated kinase 1 alters the behavior of renal cell
carcinoma. Int J Cancer 2007, 121(9):1930–1940.
86. Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan HY, Chan QK,
Chan DC, Chan KY, Cheung AN: Differential expression and
phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on
prognosis and cell invasion. Int J Cancer 2010, 127(1):21–31.
87. Teo M, Manser E, Lim L: Identification and molecular cloning of a
p21cdc42/rac1-activated serine/threonine kinase that is rapidly
activated by thrombin in platelets. J Biol Chem 1995,
270(44):26690–26697.
Tse and Ching Journal of Molecular Signaling 2014, 9:7 Page 9 of 9
http://www.jmolecularsignaling.com/content/9/1/788. Mahlamaki EH, Kauraniemi P, Monni O, Wolf M, Hautaniemi S, Kallioniemi A:
High-resolution genomic and expression profiling reveals 105 putative
amplification target genes in pancreatic cancer. Neoplasia 2004,
6(5):432–439.
89. Gong W, An Z, Wang Y, Pan X, Fang W, Jiang B, Zhang H: P21-activated
kinase 5 is overexpressed during colorectal cancer progression and
regulates colorectal carcinoma cell adhesion and migration. Int J Cancer
2009, 125(3):548–555.
90. Kaur R, Yuan X, Lu ML, Balk SP: Increased PAK6 expression in prostate
cancer and identification of PAK6 associated proteins. Prostate 2008,
68(14):1510–1516.
doi:10.1186/1750-2187-9-7
Cite this article as: Tse and Ching: The role of p21-activated kinases in
hepatocellular carcinoma metastasis. Journal of Molecular Signaling 2014 9:7.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
